PANGU INNOVATION Corp.
Update：2026/10/21
Industries
Main Industry
Biotechnology
Main Product/Service
Oocyte Reprogramming Technology
Founded Year
2026
Unified Business No.
60365886
Status
Active
Number of Employees
0
Total Paid-in
Capital
1,250,000 (NT$)
Location of Company
Taiwan
, Taipei City
Website
Company names, registration status, legal representatives, founding years, paid-in capital, registered addresses, and other details are sourced from business registration records maintained by Taiwan’s Administration of Commerce, Ministry of Economic Affairs. Exit status includes Emerging Stock Board listings, M&A, and IPOs. Information on overseas expansion is self-reported by startups.
Note 1: FINDIT compiles company information from public and other sources for reference and does not serve as a point of contact for the companies listed.
Note 2: Some company profiles and product/service descriptions are translated using AI and provided for reference only. In case of discrepancies or ambiguity, the original text prevails.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
PANGU INNOVATION was established in Taiwan by Nuwa Reprogramming, a startup founded on technology originating from the team of John B. Gurdon, a Nobel Prize laureate in Physiology or Medicine. The company focuses on the research and development of regenerative medicine and cell reprogramming technologies. With “oocyte molecular reprogramming technology” at its core, the company promotes cellular rejuvenation through epigenetic regulatory mechanisms and is committed to developing safe anti-aging and regenerative medicine solutions with clinical application potential. Compared to traditional induced pluripotent stem cell (iPSC) technology, PANGU INNOVATION employs a non-gene-insertion cell reprogramming strategy, which reduces the safety risks associated with genetic modification and enhances the controllability of the cell rejuvenation process. The company also leverages Taiwan’s industrial strengths in clinical medicine, biotech manufacturing, and artificial intelligence applications to advance the development and application of cell reprogramming technology in the fields of regenerative medicine and precision medicine.
